@@ Click here For Free Trail
X
Introduce Yourself
I wish to receive Newsletter, Promotional SMS and Special Information
The above information provided by you kept strictly confidential and is not used for any other purpose than sending you trading calls. "We don't SPAM you".
Passion
  •  
Support : +91 90525 24345
Call : +91 77948 69869
Whatsapp : +91 98489 69869
  • NSE
  • BSE
stock alerts / Lupin in focus as EU Court upholds fine in Perindopril litigation
Lupin in focus as EU Court upholds fine in Perindopril litigation
Dec 13 2018

Indian Intraday Stock Market Shares of Lupin announced that the General Court of the European Union has delivered its judgment concerning Lupin's and other companies appeal against the European Commission's (EC) 2014 decision in the Perindopril litigation. The General Court upheld the EC's decision holding Lupin liable to pay a fine of EUR 40 million. Lupin will study the General Court's judgment and evaluate further course of action. The announcement was made after market hours yesterday, 12 December 2018.

 
DLF said that the company's board of directors has considered and approved offering upto 17.30 crore equity shares in one or more tranches by way of private placement, including Qualified Institutions Placement (QIP). The announcement was made after market hours yesterday, 12 December 2018.
 
Indian Oil Corporation's board meets today to consider and approve buyback of equity shares and interim dividend.
 
Strides Pharma Science (Strides) announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Lidocaine Ointment USP 5% from the United States Food & Drug Administration (US FDA). Lidocaine Ointment is a generic version of Xylocaine Ointment of AstraZeneca Pharmaceuticals LP. The announcement was made after market hours yesterday, 12 December 2018.
 
Infibeam Incorporation said that the meeting of the board of directors of the company is scheduled on 17 December 2018 to consider and approve examine and evaluate the feasibility of and options for strategic growth opportunities of the business verticals and subsidiaries of the company. The announcement was made after market hours yesterday, 12 December 2018.